Reset filter
Trefwoorden
N05.715.360.775.175.250.350 ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

730 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Follow-Up - Follow-Up Oncology

- 02-11-15 - 1 Formulier, 5 Itemgroepen, 16 Data-elementen, 19 Talen
Itemgroepen: Identity, Diagnosis, Therapy, Study, Follow-up
Follow Up Dokumentation zur automatischen Berechnung von Kaplan-Meier Kurven.

Pancreatic Cancer NCT00058149 Follow-Up - Hematology/Chemistry Form - 2048132v3.0 - Hematology/Chemistry Form

- 21-01-15 - 1 Formulier, 2 Itemgroepen, 31 Data-elementen, 1 Taal
Itemgroepen: Header, Hematology and Chemistry
Hematology/Chemistry Form A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A65D4877-9B57-427A-E034-0003BA0B1A09

Study SHIP-TREND_TREND1_MEX - t1.dupuytren

- 26-10-24 - 33 Formulieren, 1 Itemgroep, 15 Data-elementen, 2 Talen
Itemgroep: t1.dupuytren
SHIP study https://doi.org/10.1093/ije/dyac034

t1.kneescore

1 Itemgroep 34 Data-elementen

t1.thyroidu

1 Itemgroep 40 Data-elementen

t1.echoallg

1 Itemgroep 29 Data-elementen

t1.liverus

1 Itemgroep 20 Data-elementen

t1.ogttint

1 Itemgroep 17 Data-elementen

t1.sum10

1 Itemgroep 64 Data-elementen

Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593 - Physical Examination, Laboratory Results Hematology/ Chemistry Follow- Up

- 31-01-22 - 1 Formulier, 8 Itemgroepen, 44 Data-elementen, 1 Taal
Itemgroepen: Date of physical examination, Visit Week physical examination, B- Symptoms, Physical Examination, Organ/ System, Visit Week laboratory, Hematology, Chemistry
Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Follow-up AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - Follow-up AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 17-11-21 - 1 Formulier, 5 Itemgroepen, 22 Data-elementen, 1 Taal
Itemgroepen: Follow-up, Concomitant Disease, Therapy, Allogenic Transplantation, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Breast Cancer NCT01101438 Follow-Up - NCIC MA.32 Telephone Follow-Up Report - 3025096v1.0 - NCIC MA.32 Telephone Follow-Up Report

- 27-09-21 - 1 Formulier, 5 Itemgroepen, 17 Data-elementen, 1 Taal
Itemgroepen: TIMING OF REPORT - TELEPHONE FOLLOW-UP, METFORMIN/PLACEBO ADMINISTRATION, SERIOUS ADVERSE EVENT - QUESTION, ADVERSE EVENTS ON TREATMENT - QUESTION, ADVERSE EVENTS
NCIC MA.32 Telephone Follow-Up Report A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=81DC7457-3943-EA84-E040-BB89AD43055B

Follow-Up - Phase II Lung Cancer - Advanced Disease Follow-Up Form - 2399268v1.0 - Phase II Lung Cancer - Advanced Disease Follow-Up Form

- 27-09-21 - 1 Formulier, 9 Itemgroepen, 36 Data-elementen, 1 Taal
Itemgroepen: CRF Header, Form Administration, Lung: Vital Status, Lung: Disease Follow-Up Status, Lung: Notice of Progression/Site, Lung: Subsequent Non-Protocol Therapy, Lung: Notice of New Primary, Lung: Long-Term Toxicity, Comments
Phase II Consortium Phase II Lung Cancer - Advanced Disease Follow-Up Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF8E0C9E-44F2-3242-E034-0003BA3F9857

Follow-Up - Phase II Lung Cancer - Localized Disease Follow-Up Form - 2402852v1.0 - Phase II Lung Cancer - Localized Disease Follow-Up Form

- 27-09-21 - 1 Formulier, 9 Itemgroepen, 38 Data-elementen, 1 Taal
Itemgroepen: CRF Header, Form Administration, Lung: Vital Status, Lung: Disease Follow-Up Status, Lung: Notice of Progression/Site, Lung: Subsequent Non-Protocol Therapy, Lung: Notice of New Primary, Lung: Long-Term Toxicity, Comments
Phase II Consortium Phase II Lung Cancer - Localized Disease Follow-Up Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=00212490-27A3-4F0A-E044-0003BA3F9857

Swedish Bladder Cancer Registry - Cystectomy - Follow-Up

- 27-09-21 - 1 Formulier, 5 Itemgroepen, 106 Data-elementen, 2 Talen
Itemgroepen: General Information, Preoperative Data, Perioperative Data, Postoperative Data, Complications and Reoperations
Swedish Bladder Cancer Registry Healthcare Quality http://www.cancercentrum.se/vast/cancerdiagnoser/urinvagar/urinblase--och-urinvagscancer/kvalitetsregister/dokument/ Cystectomy - Follow-Up

Immunogenicity of malaria vaccine candidate - NCT00323622 / Malaria-039 - Visit 2: Laboratory Tests

- 27-09-21 - 1 Formulier, 4 Itemgroepen, 12 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Blood Sample for Antibodies to CS, Blood Sample for Antibodies to HBs, Blood Sample for Hematocrit
Study ID: 104297 Clinical Study ID: 104297 Study Title: An open study for a 2-year period to confirm the safety and immunogenicity of the candidate malaria vaccine RTS,S/AS02A in Mozambican children aged 1 to 4 years at the time of first vaccine dose. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00323622 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: SB257049 Trade Name: SB257049 Study Indication: Malaria This study (Malaria-039 / NCT00323622 / GlaxoSmithKline Study ID 104297) is a two-year follow-up to Malaria-026 and consists of three clinic visits: Visit 1 / Informed Consent Visit at Visit 7 of Malaria-026 (i.e. 21 months post vaccine dose 1 in Malaria-026). Visit 2 / Interim Analysis 12 months +/- 1 month after Visit 1. Visit 3 / Final Analysis 24 months +/- 1 month after Visit 1. See https://clinicaltrials.gov/ct2/show/NCT00323622 This document is to be completed at Visit 2.

Immunogenicity of malaria vaccine candidate - NCT00323622 / Malaria-039 - Visit 3: Laboratory Tests

- 27-09-21 - 1 Formulier, 4 Itemgroepen, 12 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Blood Sample for Antibodies to CS, Blood Sample for Antibodies to HBs, Blood Sample for Hematocrit
Study ID: 104297 Clinical Study ID: 104297 Study Title: An open study for a 2-year period to confirm the safety and immunogenicity of the candidate malaria vaccine RTS,S/AS02A in Mozambican children aged 1 to 4 years at the time of first vaccine dose. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00323622 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: SB257049 Trade Name: SB257049 Study Indication: Malaria This study (Malaria-039 / NCT00323622 / GlaxoSmithKline Study ID 104297) is a two-year follow-up to Malaria-026 and consists of three clinic visits: Visit 1 / Informed Consent Visit at Visit 7 of Malaria-026 (i.e. 21 months post vaccine dose 1 in Malaria-026). Visit 2 / Interim Analysis 12 months +/- 1 month after Visit 1. Visit 3 / Final Analysis 24 months +/- 1 month after Visit 1. See https://clinicaltrials.gov/ct2/show/NCT00323622 This form is to be completed at/after Visit 3.

Immunogenicity, safety and reactogenicity of combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) in healthy children (100565) - Long-Term Follow-Up (Visit 12, Year 9) - Informed Consent; Demographics; Laboratory Tests; Follow-Up Studies; Tracking Document

- 27-09-21 - 1 Formulier, 7 Itemgroepen, 28 Data-elementen, 1 Taal
Itemgroepen: Administrative, Informed Consent, Demographics, Laboratory Tests, Follow-Up Studies, Tracking Document - Reason for non participation, Investigator signature
Study ID: 100565 Clinical Study ID: 100565 Study Title: An open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' commercially available combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Phase: phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial